Loading
companiesCompany
InxMed
InxMed is a Shanghai biotechnology company developing IN10018 (ifebemtinib), a focal adhesion kinase inhibitor, which is in a phase 3 trial with the KRAS G12C inhibitor garsorasib against standard therapy in KRAS G12C-mutant lung cancer.
Also called: InxMed (Shanghai) Co., Ltd.应世生物InxMed (Shanghai)inxmed-shanghai
Overview
InxMed, based in Shanghai, develops drugs against the tumour microenvironment and drug resistance. Its lead candidate IN10018 (ifebemtinib) inhibits focal adhesion kinase (FAK), a signal that helps tumours resist KRAS inhibitors and chemotherapy, and is being tested in a phase 3 trial combined with the KRAS G12C inhibitor D-1553 (garsorasib) against standard therapy in non-small-cell lung cancer, as well as in platinum-resistant ovarian cancer. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Headquarters
Shanghai, CN
Scorecard
All companies#300of 1244 companies, score 14
- phase 3 +3
- targets +2
- modalities +2
- registry trials +7
0 approved, 1 in phase 3, 0 earlier, 1 targets, 14 registry studies. Formula on the scorecards page.
Type
Stage
Growth stage
Website
Phase 3small molecule
IN10018 is an experimental small-molecule drug from InxMed (Shanghai) in phase 3 trials for non-small-cell lung cancer, pancreatic ductal adenocarcinoma and ovarian cancer, with its target not yet stated publicly.
Similar pages
- TargetFAK (PTK2)
Shares IN10018, Ovarian cancer, Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer.
- TreatmentFurmonertinib
Shares IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC, Non-small-cell lung cancer.
- TreatmentPegylated liposomal doxorubicin
Shares IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurren, Ovarian cancer.
cancers
fronts
drugs
Phase 3small molecule
trials
A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C MutationIN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLCIN10018 Combination Therapy in Treatment-naïve ES-SCLCIN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant RecurrenIN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian CancerIN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer